Results 151 to 160 of about 28,388 (258)

Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]

Diabetes Obes Metab
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB.   +5 more
europepmc   +1 more source

Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real‐World, Database Study

Journal of Evidence-Based Medicine, EarlyView.
ABSTRACT Objective Although concerns have been raised that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may increase the risk of bowel obstruction or ileus, evidence remains inconclusive. In this context of uncertainty, we examined the frequency and determinants of GLP‐1RA discontinuation after hospitalization for bowel obstruction/ileus ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. [PDF]

Gut Liver
Ko Y, Hur MH, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.   +10 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.

JAMA Netw Open
Turchin A, Petito LC, Hegermiller E, Carnahan R, DeVries A, Goel S, Lansang MC, McDonnell ME, Nair V, Priest E, Willey VJ, Kaul AF, Hernán MA.   +12 more
europepmc   +1 more source

Heterogeneous effects of sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors on nephrolithiasis in older adults with type 2 diabetes. [PDF]

Pharmacotherapy
Radwan RM, Huang W, Li Y, Shao H, Guo Y, Zhang Y, Fonseca V, Shi L, Huang Y, Schatz D, Bian J, Guo J.   +11 more
europepmc   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai, Gil Caspi, Akhilanand Chaurasia, Gavriel Chaushu, Daya Masri, Ehud Jonas   +5 more
wiley   +1 more source

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. [PDF]

Clin Transl Sci
Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

Biological definition of periodontal diseases: A historical review of host‐response diagnostics and their implications for disease classification

Periodontology 2000, EarlyView.
Abstract Background Understanding periodontal diseases through a biological lens has been a central aim in periodontal research. Visionary pioneers in the field established the foundations of our knowledge, providing invaluable insights into disease mechanisms and progression.
Nagihan Bostanci, Melissa M. Grant, Moritz Kebschull   +2 more
wiley   +1 more source

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology

Journal of Diabetes Investigation, 2019
Takaaki Murakami, Daisuke Yabe, Nobuya Inagaki   +2 more
doaj   +1 more source